Richmond life sciences laboratory product company Grenova has appointed Richard Pellegrino as its chief research and development officer.
The move comes as Grenova continues to grow under the guidance of CEO Lane Major, a co-founder of Leesburg, Virginia, medical implant company K2M who took the lead role with the Richmond company earlier this year.
"Richard will make an immediate impact as Grenova continues to grow its team of industry leaders committed to proprietary technology that is providing a unique economic, environmental and supply chain value proposition to our customers around the world," Major said in a statement.
Grenova manufactures technology that washes and sterilizes devices used in diagnostic testing, allowing them to be reused rather than thrown away.
Like Major, Pellegrino is a veteran of K2M, having served in R&D and technology executive roles with the company from 2012 to 2019. K2M was sold to medical manufacturing company Stryker Corp. in 2018 for $1.4 billion, and Pellegrino stayed on as senior director of R&D. He also currently serves as an entrepreneur in residence at Richmond’s Virginia Commonwealth University, advising its tech transfer program.
Connecticut private equity firm Peloton Equity purchased a majority share in Grenova in 2022 and Major's hiring as CEO followed. He replaced founder Ali Safavi, who kept a seat on the company's board.
Pellegrino’s hiring follows Grenova’s June hire of Katherine Marrs, also a former Stryker employee, as its chief commercial officer.
